drugset
drugset / Trial / NCT06393335

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06393335 ↗

Phase 0 Unknown 36 enrolled The Children's Hospital of Zhejiang University School of Medicine Leman Biotech Co., Ltd. · collab
NaSequentialOpen-labelTreatment

Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies

Timeline

Start
2024-05-15
Primary completion
2026-03-01
Completion
2026-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Metabolically Armed CD19 CAR-T cells Cell therapy — Intravenous

Indications

acute lymphoblastic leukemia